Business, energy, technology, markets and global industry news from Business News Today

iadademstat

PharmaDeviceNews iadademstat
Representative image illustrating leukemia treatment research as Oryzon Genomics reports a 95% response rate with its experimental iadademstat combination in an early-stage acute myeloid leukemia trial.
Pharma & Biotech

Iadademstat shows 95% response rate in leukemia as Oryzon Genomics prepares Phase 3 development

Oryzon Genomics reports a 95% AML response rate with iadademstat. See the remission findings, survival data and plans for Phase 3 trials.

Read More
Pharma & Biotech

Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?

Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.

Read More